Teva Nabs Approval to Market Generic GSK Inhaler

Jan 30, 2017


Teva Pharmaceutical Industries has received U.S. approval to market a copy of GlaxoSmithKline's Advair inhaler, called AirDuo RespiClick, according to a Reuters article.

Teva's version of GSK's medicine is not a direct substitute for Advair and is only approved for asthma, while Advair is also used for chronic obstructive pulmonary disease (COPD), the story said.

AirDuo offers the same two drugs as Advair--fluticasone propionate and salmeterol--but it delivers a lower dose of salmeterol. It also uses Teva's Respiclick inhaler rather than a copy of GSK's device.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments